Alkem Laboratories FY26 Performance

Alkem Laboratories reported record EBITDA of ₹30,052 million for the fiscal year 2026, marking a 19.6% year-on-year increase. The company's revenue from operations for FY26 reached ₹147,123 million, up 13.5% from the previous year.

Reader Takeaway: Strong annual growth driven by operations; quarterly profit hit by one-off charges. Regulatory observations are a key watch point.

What just happened

Alkem Laboratories announced its financial results for the fourth quarter and full fiscal year 2026. The company achieved its highest-ever EBITDA of ₹30,052 million for FY26, alongside a 13.5% year-on-year revenue growth to ₹147,123 million. However, the fourth quarter of FY26 saw a 22.7% year-on-year decline in Profit After Tax (PAT) to ₹2,365 million. This quarterly dip was significantly influenced by exceptional charges amounting to ₹1,350 million.

Why this matters

The record annual EBITDA and steady revenue growth indicate strong underlying business performance and operational efficiency throughout the year. However, the decline in quarterly PAT due to exceptional items signals potential short-term pressures on profitability. Furthermore, regulatory observations at a manufacturing facility could pose future operational challenges if not addressed effectively.

The backstory

Alkem Laboratories has been focusing on expanding its domestic and international market presence. The company consistently invests in research and development to bolster its product pipeline. In FY26, R&D investments stood at ₹6,173 million. The company maintains a healthy net cash position of ₹54.74 billion as of March 31, 2026.

What changes now

Investors will be looking for management's strategy to address the 7 observations in the Form 483 received for the Daman facility. The company is in the process of submitting its audit response. The impact of exceptional items on Q4 profitability is temporary, but the ongoing resolution of regulatory issues will be crucial for future operational continuity and investor confidence.

Risks to watch

The primary risk highlighted is the regulatory observation at the Daman facility. The company needs to successfully address these observations to avoid potential disruptions. Additionally, while exceptional items impacted Q4, any recurring unforeseen costs could affect future profitability.

Peer comparison

(No specific peer data provided in the filing)

Context metrics (time-bound)

• FY26 Revenue: ₹147,123 Mn (13.5% YoY growth)
• FY26 EBITDA: ₹30,052 Mn (19.6% YoY growth)
• Q4 FY26 Revenue: ₹36,033 Mn (14.6% YoY growth)
• Q4 FY26 PAT: ₹2,365 Mn (-22.7% YoY change)
• Exceptional Charges (Q4 FY26): ₹1,350 Mn
• Net Cash (as of 31st March 2026): ₹54.74 billion
• R&D Spend (FY26): ₹6,173 Mn

What to track next

Investors should monitor the company's progress in resolving the regulatory observations at its Daman facility and any further updates on operational impact. Future quarterly results will also be key to assessing the recovery from the exceptional charges and continued revenue momentum.